- Conditions
- Cystic Fibrosis
- Interventions
- Vancomycin hydrochloride inhalation powder, Placebo inhalation powder
- Drug
- Lead sponsor
- Savara Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1921–1944
of 12,560
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphedema
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Aortic Aneurysm
- Interventions
- EndoAnchor™, endovascular treament
- Device · Procedure
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,090 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
- Conditions
- Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
- Interventions
- 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab, Avelumab, Pembrolizumab, Retifanlimab
- Drug
- Lead sponsor
- Ariceum Therapeutics GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 6
- States / cities
- Miami, Florida • Louisville, Kentucky • Glen Burnie, Maryland + 3 more
- Conditions
- Chronic Low-back Pain
- Interventions
- LY3556050, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 27 more
- Conditions
- Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity
- Interventions
- management of therapy complications
- Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 9 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Stanford, California • Miami, Florida + 21 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Lunsekimig, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 942 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 73
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Surprise, Arizona + 59 more
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
- Interventions
- Orca-T, Standard-of-Care
- Biological
- Lead sponsor
- Orca Biosystems, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 19
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 14 more
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Ripretinib, Sunitinib
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 43
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 38 more
- Conditions
- Primary Sjogren's Disease
- Interventions
- Telitacicept, Placebo
- Biological · Drug
- Lead sponsor
- Vor Biopharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 47
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Glendale, Arizona + 41 more
- Conditions
- Alcohol Use
- Interventions
- Counseling, mHealth
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Coral Gables, Florida • Gainesville, Florida
- Conditions
- Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
- Interventions
- ADI-001, Fludarabine, Cyclophosphamide
- Genetic · Drug
- Lead sponsor
- Adicet Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 10
- States / cities
- Stanford, California • Miami, Florida • Atlanta, Georgia + 7 more
- Conditions
- HIV Infection
- Interventions
- emtricitabine/tenofovir, abacavir/lamivudine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 688 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
- Conditions
- Traumatic Fracture, Pathological Fracture
- Interventions
- IlluminOss Device
- Device
- Lead sponsor
- IlluminOss Medical, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 300 participants
- Timeline
- 2021 – 2026
- U.S. locations
- 13
- States / cities
- Mobile, Alabama • Los Angeles, California • Denver, Colorado + 10 more
- Conditions
- Mild Traumatic Brain Injury
- Interventions
- Passive neurosensory reintegration training (PNRT)
- Device
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Malignant Melanoma
- Interventions
- ABI-007, Dacarbazine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 529 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 33 more
- Conditions
- Advanced Unresectable Solid Tumors, BRAF-mutated Tumors
- Interventions
- FORE8394
- Drug
- Lead sponsor
- Fore Biotherapeutics
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Orange, California • Stanford, California + 9 more
- Conditions
- Knee Cartilage Defects
- Interventions
- CARTISTEM® + Debridement, Debridement
- Biological · Procedure
- Lead sponsor
- Medipost, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 32 more
- Conditions
- Atopic Dermatitis, Skin Diseases
- Interventions
- Orismilast modified release tablets, Placebo
- Drug
- Lead sponsor
- UNION therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 18
- States / cities
- Canoga Park, California • Fountain Valley, California • Inglewood, California + 13 more
- Conditions
- Hematologic Neoplasms
- Interventions
- Enasidenib
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 19
- States / cities
- Duarte, California • Stanford, California • Aurora, Colorado + 14 more
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
- Interventions
- Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 18 Months
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 193
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more
- Conditions
- Plaque Psoriasis
- Interventions
- 188-0551 Spray, RLD
- Drug
- Lead sponsor
- Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Thousand Oaks, California • Miami, Florida
- Conditions
- Cardiac Toxicity, Lymphoma
- Interventions
- bleomycin sulfate, filgrastim, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2008
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 45 more
- Conditions
- Outcomes, Survival Rates
- Interventions
- CMX001
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 100 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 47
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 30 more